Friday, Nov 16 2018 | Time 00:04 Hrs(IST)
image
Business Economy Share

Strides enters into strategic partnership with SUDA Pharmaceuticals for US market

Strides enters into strategic partnership with SUDA Pharmaceuticals for US market

Mumbai, Nov 09(UNI) Pharma Strides Pharma Science Limited today said that its step-down wholly owned subsidiary, Strides Pharma Global Pte Limited, Singapore has entered into an exclusive product development, licensing and supply agreement with SUDA Pharmaceuticals Ltd (ASX: SUD) for its novel drug SUD-001H, an oral spray of sumatriptan to treat migraine headache for the US market.

Execution of Strides' generic product pipeline for the US is nearing completion and is expected to have 150+ ANDA filings by 2021. The company is now focusing on developing a portfolio of complex and specialty products including products filed under the 505B (2) regulatory pathway., company said in afiling with BSE.

The company through inhouse development and partnerships will build a portfolio of limited competition products offering exclusivity for a sustainable period. Today's announcement of partnership with SUDA is part of company's specialty portfolio buildout for the US market.

Sumatriptan is one of the most widely used drugs for the treatment of acute migraine in adults. SUD-001H is a first-in-class mint-flavoured oral spray formulation of sumatriptan (marketed in tablet form and in a nasal spray by GlaxoSmithKline under the brand name Imitrex).

The product will be filed with the USFDA under the 505B (2) regulatory pathway and on approval is expected to be the first fast-acting oral spray of sumatriptan in the US market. The product will utilize SUDA's recently developed proprietary OroMist® hydrotrope technology that significantly improves the rate of absorption and the quantity of drug that is absorbed across the mucosal membranes. A primary market assessment on the potential for SUD-001H for the treatment of adult migraine confirmed the need for a product that could demonstrate a faster onset of action and the same was supported by medical practitioners.

Under terms of the agreement SUDA will provide product development services for SUD-001H funded by Strides SUDA to work with Strides team through joint committees to achieve successful USFDA approval for the product SUDA to receive an upfront cash payment of US$ 0.4 Mn and a further payment of US$ 0.6 Mn on reaching certain milestones including the pilot first-in-man clinical study, submission and approval of the product in the US.On commercial sales, SUDA will receive royalties plus a handling fee

Strides to have a right of first refusal for additional territories including the European Union, Australia and New Zealand, Canada, South Africa and Japan.

UNI JS SY 1219

More News

Energy conservation must to save earth from destruction: Jai Ram Thakur

15 Nov 2018 | 8:47 PM

Shimla, Nov 15 (UNI) Expressing concern over fast-depleting natural resources, Chief Minister Jai Ram Thakur on Thursday said that energy conservation plays a pivotal role as ithout it the world would deplete its natural resources and the humanity would have to depend on alternative energy resources, which comes at the cost of creating an enormous destructive waste products causing adverse impact on mother earth.

 Sharesee more..
Sensex recovers by 118 55 pts on firm Asian cues amidst softening crude oil prices

Sensex recovers by 118 55 pts on firm Asian cues amidst softening crude oil prices

15 Nov 2018 | 8:46 PM

Mumbai, Nov 15 (UNI) The benchmark index of Bombay Stock Exchange (BSE) rebounded on Thursday by 118.

 Sharesee more..

15 Nov 2018 | 8:42 PM

Major gainers were Adani Ports & SEZ, Kotak Mahindra Bank, Hero MotoCorp, Axis Bank and Vedanta, rising by up to 4.

 Sharesee more..

Telecom: 20 lakh BTSs and 5 lakh mobile towers installed

15 Nov 2018 | 7:33 PM

New Delhi, Nov 15 (UNI) The telecom industry has installed five lakh mobile towers, taking the total BTS (base transceiver station) count to over 20 lakh, a statement here said.

 Sharesee more..

Infosys appoints Jayesh Sangharika as interim CFO

15 Nov 2018 | 7:27 PM

Bengaluru, Nov 15 (UNI) IT major Infosys Board of Directors have approved appointment of Mr Jayesh Sanghrajka as the interim Chief Financial Officer (CFO) with effect from November 17, 2018.

 Sharesee more..
image